Triple-negative breast cancer (TNBC), an aggressive subtype lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, accounts for 10-20% of breast cancers and is characterized by high metastatic potential and poor survival outcomes. This evidence concerns the gene ERBB2 and breast carcinoma.